GHK-Cu Reconstitution Calculator

No for injectable anti-aging, recovery, or performance use (practitioner consensus). GHK-Cu has human clinical use only in limited topical/wound contexts; a placebo-controlled diabetic ulcer study found faster plantar ulcer closure and fewer infections with topical GHK-Cu gel, but this does not establish approval for injectable systemic use (human controlled trial). Recent reviews describe GHK-Cu as promising in dermatology, wound repair, and regenerative applications, but still investigational for most indications (review).

Most real-world use clusters into skin repair, wound support, hair/scalp support, and experimental anti-inflammatory or anti-fibrotic protocols (preclinical/review). Mechanistically, it has been linked to collagen and glycosaminoglycan support, matrix remodeling, antioxidant effects, angiogenesis, and reduced inflammatory signaling (mechanistic/preclinical). Animal and cell studies also suggest activity in lung inflammation/fibrosis and airway remodeling via redox and SIRT1-related pathways, but these are not proven human treatment uses (animal/in-vitro).

Topical has the best direct human support for wound/skin use; injectable and intranasal are mostly experimental (human controlled trial; animal). In mice, intraperitoneal 15 mg/kg daily for 5 days and intranasal 15 mg/kg daily for 8 weeks both improved behavioral outcomes, but produced different transcriptional patterns, suggesting route and duration matter biologically (animal). For practical use, topical is preferred for skin targets, while subcutaneous/intramuscular microdosing is a community protocol for systemic or localized soft-tissue goals; oral use is generally considered poor because peptide stability and absorption are uncertain (community protocol).

Human dose-finding trials are lacking, so injectable dosing is mostly practitioner consensus/community protocol. Common protocols use 1-2 mg/day subcutaneously, often split as 500-1000 mcg once or twice daily for 4-8 weeks for skin, recovery, or generalized repair (community protocol). Localized injury protocols often use 1-2 mg/day near the target area for 2-6 weeks (community protocol). Topical cosmetic preparations commonly use low-concentration peptide systems in serums/creams; liposomal formulations are used to improve delivery and stability (formulation/preclinical).

Evidence supports short- to medium-duration cycles better than indefinite use (animal/review). Preclinical studies used 5 days intraperitoneal or 8 weeks intranasal in mice, with biologic effects seen across both schedules (animal). In practice, 4-8 week cycles are common, followed by reassessment or time off (community protocol). For topical skin care, longer continuous use is common because exposure is lower and local rather than systemic (practitioner consensus).

Topical GHK-Cu appears generally well tolerated in skin-focused studies and product-development work (human controlled trial; formulation studies). Main expected issues with injectable use are injection-site irritation, transient redness, bruising, swelling, and uncertainty around sterility/compounding quality (community protocol). Because GHK-Cu is a copper complex, stacking multiple copper-containing products or using it in people with disorders of copper handling is a caution area; mechanistic papers emphasize copper binding and redox biology, but do not establish safe high systemic dosing in humans (mechanistic). Pregnancy, breastfeeding, and pediatrics lack meaningful safety data; avoid except under physician supervision (evidence gap).

There is preclinical rationale, not clinical proof (animal/review). GHK-Cu reduced inflammatory signaling and oxidative stress in zebrafish inflammation models, improved stress resistance and lifespan markers in C. elegans, and altered hippocampal aging programs in mice (animal). These data support experimental interest, but not established human protocols for cognition, longevity, colitis, COPD, or fibrosis. If used for such goals, it should be framed as exploratory and not equivalent to evidence-based therapy (review/preclinical).

Dry peptide powder is typically more stable than reconstituted solution, while carrier/formulation stability is a known issue for peptide products (formulation/review). Community practice is to refrigerate reconstituted injectable peptide at 2-8 °C, protect from light, and discard if cloudy or contaminated (community protocol). For travel, keep reconstituted vials cool with an insulated pack, carry labeled prescription/clinic documentation if applicable, and avoid heat exposure. Topical finished products follow manufacturer storage instructions; liposomal and peptide systems can lose performance if poorly stored (formulation).